Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation

NACompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Hepatitis C, ChronicNon-Alcoholic Fatty Liver Disease
Interventions
DEVICE

Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123)

"The FDA has indicated that liver function diagnostic testing with stable isotope labeled cholates would be considered a drug/device combination product. The drugs administered at each test visit will be:~20 mg Cholate-24-13C, IV (in the vein), dissolved in NaHCO3 and mixed with albumin.~40 mg Cholate-2,2,4,4-d4, oral, dissolved in NaHCO3 and mixed with juice.~The 3 test visits will be on separate days within a span of 30 days"

Trial Locations (1)

80045

University of Colorado Hospital, Aurora

Sponsors

Lead Sponsor

All Listed Sponsors
lead

HepQuant, LLC

INDUSTRY

NCT01579162 - Intra-Individual Reproducibility of the Non-Invasive Assessment of the Portal Circulation | Biotech Hunter | Biotech Hunter